A treatment paradox has recently come to light in prostate cancer: Blocking testosterone production halts tumour growth in early disease while...
Vous n'êtes pas connecté
Quantum BioPharma (CSE:QNTM) will conduct a study observing disease progression in patients with primary progressive multiple sclerosis.
A treatment paradox has recently come to light in prostate cancer: Blocking testosterone production halts tumour growth in early disease while...
MONDAY, Sept. 16, 2024 -- Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that...
MONDAY, Sept. 9, 2024 -- Cancer diagnosis is associated with an increased risk for psychological illness and cardiovascular disease among...
THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen...
FRIDAY, Sept. 13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with...
A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive decline in Alzheimer’s...
A recent study from the University of Bristol has uncovered a promising new method to slow the progression of diabetic kidney disease, a condition...
THURSDAY, Sept. 5, 2024 -- Lung function remains stable over three years after hematopoietic cell transplant (HCT) among patients with sickle cell...
FRIDAY, Sept. 6, 2024 -- The most reliable approach to reclassifying patients with probable Meniere disease (MD) includes the combination of...
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.